Research progress of fibroblast activation protein-targeted radiopharmaceuticals in tumor radionuclide internal radiation therapy
10.3760/cma.j.cn321828-20240717-00264
- VernacularTitle:FAP靶点类放射性药物用于肿瘤核素内照射治疗的研究进展
- Author:
Xuezhi LIN
1
;
Haiwen LU
;
Guojian ZHANG
Author Information
1. 内蒙古医科大学第一临床医学院，呼和浩特 010050
- Publication Type:Journal Article
- Keywords:
Neoplasms;
Radiopharmaceuticals;
Membrane proteins;
Fibroblasts;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2025;45(7):435-440
- CountryChina
- Language:Chinese
-
Abstract:
Fibroblast activation protein (FAP), highly expressed in cancer-associated fibroblasts, is closely related to changes in the tumor microenvironment. Radionuclide-labeled FAP inhibitor (FAPI) is a novel tumor therapeutic agent targeting FAP. It can specifically bind to FAP and emit radiation-killing signals, and has been gradually applied to tumor radionuclide internal radiation therapy (IRT). This review summarizes the research progress of various FAP-targeted radiopharmaceuticals in tumor radionuclide IRT, aiming to gain a deeper understanding of their intrinsic properties and promote broader clinical applications.
